GLP-1 side effects: common, uncommon, and when to ask for help

Most people starting a GLP-1 medicine want the same two things: a realistic picture of what the first weeks will feel like, and a clear line between “this is normal” and “this needs a clinician.” The trials answer the first question well. The second question is where calm, specific knowledge matters most — because the rare problems are the ones worth recognising early.

This page distils what the medicines’ own large trials and labels report. It describes; it does not prescribe. It contains no doses, and it is not a substitute for the person who knows your history.

One caveat before the symptoms: pregnancy. These medicines are not recommended in pregnancy or while breastfeeding, and some (such as tirzepatide) can make oral contraception less reliable. If you could become pregnant, contraception and any plan to conceive are a conversation to have with your prescriber before starting — not after.

What strong evidence says

The dominant side effects of GLP-1 and dual/triple-agonist medicines are gastrointestinal, and this sits on the top rung of the Evidence Ladder: consistent findings across several large randomised trials of approved drugs used for their approved purpose.

In STEP 1, the semaglutide trial in obesity, gastrointestinal events — most often nausea, diarrhea, vomiting, and constipation — were the most frequently reported events, occurring in about three-quarters of people on the drug versus roughly half on placebo. Crucially, they were typically mild-to-moderate, transient, and tended to subside over time. The same pattern repeats with tirzepatide in SURMOUNT-1 and with semaglutide in the very large SELECT cardiovascular trial, where the GI profile was the main driver of side-effect-related discontinuation but most participants continued treatment.

Three things are well-established about these common effects:

• They cluster around dose increases. Symptoms tend to appear or worsen when the dose steps up, which is part of why titration schedules exist — they are a side-effect-management tool, not an arbitrary delay.
• They usually settle. For most people the nausea curve bends down with time rather than up.
• They are manageable for most, but not all. A minority stop because of GI symptoms; in STEP 1 that was a small single-digit percentage, higher than placebo but far from universal.

Beyond the common GI effects, the labels also document uncommon-but-serious events as a class signal: acute pancreatitis, acute gallbladder disease (gallstones and inflammation, partly linked to rapid weight loss), and gastrointestinal effects severe enough to matter — ileus, intestinal obstruction, and severe constipation with fecal impaction. These are not common, but they are real, documented, and the reason a few symptoms deserve a low threshold for seeking care. The Wegovy label also carries a boxed warning about thyroid C-cell tumours seen in rodents, with the drug contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

What weaker evidence suggests

Not everything discussed around GLP-1s is equally settled.

Loss of lean mass during rapid weight loss is frequently raised. It is true that a portion of weight lost is lean tissue: dedicated body-composition substudies of these trials, using DXA scans, do report that some of the loss is lean mass alongside the larger fat-mass reduction (the STEP 1 analysis for semaglutide and the SURMOUNT-1 DXA substudy for tirzepatide). But the leap from “lean mass on a scan” to a proven decline in real-world strength, falls, or fractures is emerging and unproven, not established. The scan number is not the same as a functional outcome, and the long-term clinical significance is still being worked out.

The ileus and obstruction signal deserves an honest grade too: it appears on labels and in pharmacovigilance reporting, but much of the supporting real-world data is observational, which can show association without proving the rate or the cause. That is enough reason to take the symptom seriously — not enough to state a precise risk.

Finally, the investigational triple agonist retatrutide produced large weight loss in a phase 2 trial, with a side-effect profile dominated by the same dose-related, mostly mild-to-moderate GI events. Retatrutide is not FDA-approved and remains under study; its longer-term safety is genuinely not yet known.

For the rarer and newer signals people ask about most — the eye condition NAION, gallbladder problems, mood, and reproductive and cycle changes — we grade each one on its own evidence on a dedicated page: GLP-1’s lesser-known side effects.

What is unknown

• Who will struggle and who won’t. Trials report averages. There is no reliable way yet to predict in advance who will have severe nausea, who will tolerate the medicine easily, or who is a slow versus fast responder in the early weeks.
• The true rate of the rare events outside trial conditions — especially with unsupervised or non-prescription use, where adverse events go largely unreported and no real safety database exists.
• Long-term effects of the newest agents, where follow-up is still short and the investigational molecules have no multi-year human safety record.

When you see a confident number attached to any of these, treat the confidence as a red flag rather than reassurance.

Questions to ask a clinician

• What is the plan if nausea becomes severe — do I wait, adjust, or call?
• Which symptoms should prompt me to contact you immediately, and how do I reach you (and what do I do) if I can’t?
• How will we protect muscle and nutrition while I’m losing weight — what should I be eating and doing?
• Given my history, am I at any particular risk for gallbladder problems or pancreatitis?
• If I could become pregnant: what contraception do you recommend, and how long before trying to conceive should I stop?
• How will we monitor progress, and what would make us pause or change course?

Red flags / when to seek care

Common early discomfort is one thing. The following are not “ride-it-out” symptoms — they are reasons to contact a clinician promptly, and for the severe versions, to seek urgent care or your local emergency number:

• Severe or persistent abdominal pain, especially pain that is intense, radiates to the back, or comes with repeated vomiting — a possible sign of pancreatitis, which needs evaluation, not waiting.
• Pain in the upper-right abdomen, fever, or yellowing of the skin or eyes — possible gallbladder disease.
• A bloated, distended belly with vomiting and no bowel movements — possible bowel obstruction or ileus.
• Signs of dehydration from prolonged vomiting or diarrhea — dizziness, very dark or scant urine, confusion.
• Inability to keep fluids down for an extended period.

If something feels genuinely wrong in your body, that is not a claim to grade on a ladder — it is a reason to call. The titration phase asks for patience with the ordinary discomforts; it does not ask you to ignore the symptoms above.